Medivir AB (publ) (MVRBF) Stock Price, News & Analysis

Company Overview

Medivir AB (publ) is a Swedish pharmaceutical company focused on the discovery and development of medicines for cancer, with particular emphasis on treatments for solid tumors. The company develops small-molecule therapies intended to address unmet medical needs in oncology.

Medivir’s development activities have included remetinostat, a topical histone deacetylase inhibitor studied for cutaneous T-cell lymphoma, as well as other investigational compounds targeting cancer-related biological pathways. The company’s programs have progressed through collaborations, licensing arrangements and clinical development activities.

Historically, Medivir also conducted antiviral drug research and contributed to the discovery and development of simeprevir, a hepatitis C treatment commercialized through a partnership. The company is headquartered in Sweden and has worked with international pharmaceutical and biotechnology partners to advance its research and development programs.

Key Stats

• Today's Range: $0.82 to $0.82
• 50-Day Range: $0.82 to $0.82
• 52-Week Range: $0.68 to $0.82
• Volume: N/A
• Average Volume: 925 shs
• Market Capitalization: N/A
• P/E Ratio: 0.03
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:MVRBF
• CIK: N/A
• Web: www.medivir.com
• Phone: (685) 468-3100
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A